Embeda Uptake In Primary Care Depends On FDA Clearing Marketing Materials, King Says
This article was originally published in The Pink Sheet Daily
Executive Summary
After a warning letter, Embeda sales effort focuses on specialists. Firm does not see franchise threat from generics, although Remoxy will not be refiled until the middle of next year.
You may also be interested in...
King Assures Investors Embeda Marketing Materials Not Lost In DDMAC "Black Hole"
Five months after the launch of King's oral morphine Embeda, execs still await FDA approval of marketing materials.
King Assures Investors Embeda Marketing Materials Not Lost In DDMAC "Black Hole"
Five months after the launch of King's oral morphine Embeda, execs still await FDA approval of marketing materials.
King Expects Acurox Committee In April: What Are The Standards For Aversion-Based Abuse-Resistance?
King Pharmaceuticals expects up-or-down vote on formulation of immediate-release oxycodone with niacin. King will resubmit Acurox application after meeting.